LFMD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

4.060

Open

3.500

VWAP

3.81

Vol

6.12M

Mkt Cap

182.43M

Low

3.455

Amount

23.30M

EV/EBITDA(TTM)

14.37

Total Shares

46.66M

EV

113.40M

EV/OCF(TTM)

11.98

P/S(TTM)

0.74

LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.

Show More

Events Timeline

(ET)

2026-03-09

16:20:00

LifeMD Sees FY26 Adjusted EBITDA of $12M-$17M

2026-03-09

16:20:00

Company Sees Q1 Adjusted EBITDA Loss of $4M-$5M

2026-03-09

16:20:00

LifeMD Q4 Revenue $46.87M Beats Expectations

2026-01-06 (ET)

2026-01-06

08:50:00

LifeMD Closes $50M Credit Facility with Citizens Bank

2026-01-05 (ET)

2026-01-05

08:40:00

LifeMD Launches Novo Nordisk's Wegovy Pill Starting at $149 per Month

News

seekingalpha

03-10seekingalpha

LifeMD Stock Soars After Strong Q4 Performance and Upgraded Rating

Yahoo Finance

03-10Yahoo Finance

LifeMD Reports Strong Q4 and Full Year 2025 Earnings Growth

seekingalpha

03-09seekingalpha

LifeMD, Inc. Reports Strong Q4 2025 Earnings with Positive Outlook

seekingalpha

03-09seekingalpha

LifeMD Reports Q4 2025 Results Exceeding Expectations

seekingalpha

03-09seekingalpha

LifeMD Q4 Earnings Beat Expectations with Strong Guidance

Globenewswire

01-28Globenewswire

LifeMD Executives Allegedly Breached Fiduciary Duties

7 Analyst Rating

Wall Street analysts forecast LFMD stock price to rise

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

6.00

Averages

9.67

High

15.00

Current: 0.000

Low

6.00

Averages

9.67

High

15.00

H.C. Wainwright

Yi Chen

Buy

downgrade

$13 -> $9

AI Analysis

2025-11-19

Reason

H.C. Wainwright

Yi Chen

Price Target

$13 -> $9

AI Analysis

2025-11-19

downgrade

Buy

Reason

H.C. Wainwright analyst Yi Chen lowered the firm's price target on LifeMD to $9 from $13 and keeps a Buy rating on the shares following a top- and bottom-line miss in Q3. LifeMD, which is now a pure-play telehealth and pharmacy platform after the company divested its majority ownership in WorkSimpli, updated its 2025 total revenue guidance and the firm adjusted its projections accordingly, the analyst noted.

KeyBanc

Scott Schoenhaus

Overweight

downgrade

$12 -> $8

2025-11-19

Reason

KeyBanc

Scott Schoenhaus

Price Target

$12 -> $8

2025-11-19

downgrade

Overweight

Reason

KeyBanc analyst Scott Schoenhaus lowered the firm's price target on LifeMD (LFMD) to $8 from $12 and keeps an Overweight rating on the shares. The firm notes LifeMD is being impacted by low-cost compounders despite the FDA outlawing the practice earlier this year. However, KeyBanc expects cash prices for brand-name GLP-1s to continue to come down as well as stricter enforcement against compounders in FY26, which should benefit LifeMD due to its partnerships with Eli Lilly (LLY) and Novo (NVO). The firm also expects the launch of oral Wegovy in early FY26 to drive higher weight management subscribers.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LFMD

Unlock Now

Valuation Metrics

The current forward P/E ratio for LifeMD Inc (LFMD.O) is -9.78, compared to its 5-year average forward P/E of -19.10. For a more detailed relative valuation and DCF analysis to assess LifeMD Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-19.10

Current PE

-9.78

Overvalued PE

40.38

Undervalued PE

-78.57

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

7.24

Current EV/EBITDA

8.83

Overvalued EV/EBITDA

17.53

Undervalued EV/EBITDA

-3.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

1.18

Current PS

0.80

Overvalued PS

1.96

Undervalued PS

0.40

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

can you limit the choices to only 5 stocks

Intellectia · 724 candidates

Price: <= $10.00Pe Ttm: <= 15Target Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

Flux Power Holdings Inc

31.80M

Organogenesis Holdings Inc

487.34M

Sangamo Therapeutics Inc

127.97M

Aquestive Therapeutics Inc

409.93M

Traws Pharma Inc

19.42M

BTCS Inc

126.36M

Intellectia · 37 candidates

Market Cap: <= 300.00MPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

Aspen Aerogels Inc

295.88M

SelectQuote Inc

283.31M

Shattuck Labs Inc

280.96M

Atea Pharmaceuticals Inc

275.01M

JELD-WEN Holding Inc

258.00M

Tigo Energy Inc

243.42M

inom den amerikanska marknaden

Intellectia · 15 candidates

Market Cap: <= 1.50BPrice: <= $25.00Beta: HighRiskRsi 14: <= 45Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Sweetgreen Inc

820.33M

NOVONIX Ltd

222.62M

LifeMD Inc

170.40M

Treace Medical Concepts Inc

166.30M

Hf Foods Group Inc

116.17M

Pyxis Oncology Inc

103.36M

penny stocks wth great potential

Intellectia · 10 candidates

Market Cap: <= 1000.00MPrice: <= $5.00Debt Equity: <= 0.500Weekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 15.0%

Ticker

Name

Market Cap$

Iovance Biotherapeutics Inc

996.39M

Standard BioTools Inc

630.69M

NET Power Inc

575.35M

Digi Power X Inc

201.90M

LifeMD Inc

170.40M

Ton Strategy Co

163.68M

what penny stock to invest in

Intellectia · 12 candidates

Market Cap: <= 1000.00MPrice: <= $5.00Debt Equity: <= 1Weekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 15.0%

Ticker

Name

Market Cap$

Iovance Biotherapeutics Inc

996.39M

Standard BioTools Inc

630.69M

NET Power Inc

575.35M

Digi Power X Inc

201.90M

LifeMD Inc

170.40M

Ton Strategy Co

163.68M

Whales Holding LFMD

Trading Trends

People Also Watch

Frequently Asked Questions

What is LifeMD Inc (LFMD) stock price today?

The current price of LFMD is 3.91 USD — it has increased 25.32

What is LifeMD Inc (LFMD)'s business?

LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.

What is the price predicton of LFMD Stock?

Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is LifeMD Inc (LFMD)'s revenue for the last quarter?

LifeMD Inc revenue for the last quarter amounts to 7.08M USD, decreased -88.98

What is LifeMD Inc (LFMD)'s earnings per share (EPS) for the last quarter?

LifeMD Inc. EPS for the last quarter amounts to 0.41 USD, decreased -2150.00

How many employees does LifeMD Inc (LFMD). have?

LifeMD Inc (LFMD) has 304 emplpoyees as of March 11 2026.

What is LifeMD Inc (LFMD) market cap?

Today LFMD has the market capitalization of 182.43M USD.